Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting

NARecruitingINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

November 3, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Deep Vein ThrombosisIliac Vein ThrombosisIliac Vein ObstructionIliac Vein StenosisIliac Vein Compression Syndrome
Interventions
DRUG

Rivaroxaban

For anticoagulant, it is rivaroxaban 20mg once a day for 6 months.

DRUG

Aspirin

For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.

Trial Locations (1)

Unknown

RECRUITING

The First Affliated Hospital, Zhejiang University, School of Medicine, Hangzhou

Sponsors
All Listed Sponsors
collaborator

Zhejiang University

OTHER

collaborator

Ningbo No.2 Hospital

OTHER

collaborator

Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

OTHER

collaborator

The Central Hospital of Lishui City

OTHER

collaborator

Taizhou Enze Medical Center Group

OTHER

collaborator

Taizhou First People's Hospital

OTHER

collaborator

Boston Scientific Corporation

INDUSTRY

lead

First Affiliated Hospital of Zhejiang University

OTHER

NCT04694248 - Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting | Biotech Hunter | Biotech Hunter